Latest Roger Lo Stories
Researchers from UCLA's Jonsson Comprehensive Cancer Center led an international team of scientists in conducting two studies that provide critical insights into two important ways that tumors resist BRAF inhibitors.
A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.
Cancer has various ways of evading drugs used by oncologists to try and eliminate the disease. Now, new research is showing how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer.